FDA Approves Vanda Pharmaceuticals’ Fanapt(TM) For The Treatment Of Schizophrenia

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt(TM) (iloperidone) for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt(TM) to placebo and active control in patients with schizophrenia, as well as safety data from more than 3,000 patients.

More: continued here

Filed under: Pharma Industry on May 11th, 2009